Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Psychosis
Interventions
DRUG

Aripiprazole

pill, 2,5-20 mg/day, maximum 16 weeks

DRUG

Quetiapine

pill, 50-600mg/day, maximum 16 weeks

Trial Locations (9)

2100

Psychiatric Centre Copenhagen, Rigshospitalet, Copenhagen

2400

Bispebjerg Hospital, Copenhagen

2600

Glostrup Hospital, Glostrup Municipality

3400

Hillerød Hospital, Hillerød

4000

Child and Adolescent Psychiatric Department, Region Zealand, Roskilde

Psychiatric Centre Sct. Hans, Roskilde

5000

Odense University Hospital, Odense

8240

Psychiatric Hospital for Children and Adolescents, Aarhus, Risskov

9000

Aalborg Psychiatric Hospital, Aalborg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

The Psychiatric Centre for Children and Adolescents in Bispebjerg, Denmark

UNKNOWN

collaborator

Psychiatric Centre Copenhagen, Denmark

UNKNOWN

collaborator

Copenhagen Trial Unit, Center for Clinical Intervention Research

OTHER

collaborator

Albert Einstein College of Medicine

OTHER

collaborator

Research Institute for Biological Psychiatry, Sct. Hans Hospital, Denmark

UNKNOWN

collaborator

Capital Region Pharmacy, Denmark

UNKNOWN

collaborator

The Research Council for Health and Disease, Denmark

OTHER

collaborator

Allocated inheritance from Elizabeth Stevn and Niels Rindom, Denmark

UNKNOWN

collaborator

AP Moeller Foundation

OTHER

collaborator

Tryg Fonden, Denmark

UNKNOWN

lead

Anne Katrine Pagsberg

OTHER